INZY - Inozyme initiated at hold at Jefferies on need for proof-of-concept data on lead asset
Jefferies has initiated Inozyme (INZY) at hold saying proof-of-concept data on lead asset INZ-701 for two rare abnormal mineralization disorders. The firm has a $5 price target (~25% upside based on Wednesday's closing price).
For further details see:
Inozyme initiated at hold at Jefferies on need for proof-of-concept data on lead asset